An efficient targeted radiotherapy/gene therapy strategy utilising human telomerase promoters and radioastatine and harnessing radiation-mediated bystander effects

Journal of Gene Medicine

Volumn 6, Issue 8, 2004, Pages 937-947

  Boyd, Marie ^a   Mairs, Robert J ^a,b,c   Keith, W Nicol ^d   Ross, Susan C ^a   Welsh, Philip ^e   Akabani, Gamal ^e   Owens, Jonathan ^c   Vaidyanathan, Ganesan ^e   Carruthers, Ross ^a   Dorrens, Jennifer ^a   Zalutsky, Michael R ^e  

^a UNIVERSITY OF GLASGOW   (United Kingdom)

^b ROYAL HOSPITAL FOR SICK CHILDREN   (United Kingdom)

^c WESTERN INFIRMARY   (United Kingdom)

^d BEATSON INSTITUTE FOR CANCER RESEARCH   (United Kingdom)

^e DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Astatine; Bystander effects; Gene therapy; Targeted radiotherapy; Telomerase promoters

Indexed keywords

(3 IODOBENZYL)GUANIDINE I 131; ASTATINE 211; NORADRENALIN; RADIOPHARMACEUTICAL AGENT; TELOMERASE REVERSE TRANSCRIPTASE;

ALPHA RADIATION; ARTICLE; BYSTANDER EFFECT; CANCER RADIOTHERAPY; CELL KILLING; CELL SURVIVAL; CLONOGENIC ASSAY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFICACY; DRUG POTENCY; DRUG TARGETING; ELECTRON RADIATION; GENE DELIVERY SYSTEM; GENE EXPRESSION; GENE THERAPY; GENE TRANSFER; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; MOSAICISM; PRIORITY JOURNAL; PROMOTER REGION; RADIOTHERAPY; SPHEROID CELL;

ASTATINE; BYSTANDER EFFECT; CELL DEATH; CELL SURVIVAL; DOSE-RESPONSE RELATIONSHIP, DRUG; GENE THERAPY; HUMANS; NOREPINEPHRINE PLASMA MEMBRANE TRANSPORT PROTEINS; PLASMIDS; PROMOTER REGIONS (GENETICS); RADIOPHARMACEUTICALS; RADIOTHERAPY; SPHEROIDS, CELLULAR; SYMPORTERS; TELOMERASE; TRANSFECTION; TRANSGENES; TUMOR CELLS, CULTURED;

RICE STRIPE VIRUS;

EID: 12344258376     PISSN: 1099498X     EISSN: 15212254     Source Type: Journal    
DOI: 10.1002/jgm.578     Document Type: Article

References (49)

1. Jacques S Jr, Tobes MC, Sisson JC, et al. Comparison of the sodium dependence of uptake of meta-iodobenzylguanidine and norephrine into cultured bovine adrenomedullary cells. Mol. Pharmacol 1984; 26: 539-546.
2. 131I]iodobenzylguanidine. J Nucl Med 1980; 21: 349-353.
3. 131-I meta-iodobenzylguanidine. Gene Ther 1999; 6: 1147-1152.
4. 131I] meta-iodobenzylguanidine. J Gene Med 2001; 3: 165-172.
5. Wheldon TE, O'Donoghue JA, Barrett A, et al. The curability of tumours of differing size by targeted radiotherapy using 131I or 90Y. Radiother Oncol 1991; 21: 91-99.
6. Humm JL. Dosimetric aspects of radiolabelled antibodies for tumour therapy. J Nucl Med 1986; 27: 1490-1497.
7. 131I]meta-iodobenzylguanidine therapy in neuroblastoma spheroids of different sizes. Br J Cancer 1992; 66: 1048-1052.
8. Cunningham SH, Mairs RJ, Wheldon TE, et al. Radiotoxicity to neuroblastoma cells and spheroids of beta-, alpha- and Auger electron-emitting conjugates of benzylguanidine. Br J Cancer 1998; 77: 2061-2068.
9. Neshasteh-Riz A, Angerson WJ, Reeves JR, et al. Incorporation of iododeoxyuridine in multicellular glioma spheroids: implications for DNA-targeted radiotherapy using auger electron emitters. Br J Cancer 1997; 75: 493-499.
10. Neshasteh-Riz A, Mairs RJ, Angerson WJ, et al. The implications of proliferative heterogeneity for the design of DNA-targeted radiotherapy: differential cytotoxicity of alternative radioiodoanalogues of IudR to human glioma cells in monolayer or spheroid culture. Br J Cancer 1998; 77: 385-390.
11. Zalutsky MR, Vaidyanathan G. Astatine-211-labeled radiotherapeutics: an emerging approach to targeted alpha-particle radiotherapy. Curr Pharm Des 2000; 6: 1433-1455.
12. Hall EJ. Radiobiology for the Radiologist (4th edn). J. B. Lippincott: Philidelphia, 1994.
13. Ballangrud AM, Humm JL, McDevitt MR, et al. J Nucl Med 1998; 39: 188P (abstract).
14. Zalutsky MR, Akabani G, Cokgor I, et al. Neuro-Oncology 1999; 1: S65 (abstract).
15. Miller N, Whelan J. Progress in transcriptionally targeted and regulatable vectors for gene therapy. Hum Gene Ther 1997; 8 803-815.
16. Dachs GU, Dougherty GJ, Stratford IJ, et al. Targeting gene therapy to cancer: a review. Oncol Res 1997; 9: 313-325.
17. Nettelbeck DM, Jerome V, Muller R. Gene therapy: designer promoters for tumour targeting. TIG 2000; 16: 174-181.
18. Kim NW, Piatyszek MA, Prowse KR, et al. Specific association of human telomerase activity with immortal cells and cancer. Science 1994; 266: 2011-2015.
19. Shay JW, Bacchetti SA. Survery of telomerase activity in human cancer. Eur J Cancer 1997; 33: 787-791.
20. Holt SE, Shay JW. Role of telomerase in cellular proliferation and cancer. J Cell Physiol 1999; 180: 10-18.
21. Meyerson M. The role of telomerase innormal and cancer cells. J Clin Oncol 2000; 18: 477-484.
22. Nowak R, Chrapusta SJ. Regulation of telomerase activity in normal and malignant human cells. Cancer J Sci Am 1998; 4: 148-154.
23. Plumb JA, Bisland A, Kakani R, et al. Telomerase specific suicide gene therapy vectors expressing bacterial nitroreductase sensitise human cancer cells to the pro-drug CB1954. Oncogene 2001; 20: 7797-7803.
24. Majumdar AS, Hughes DE, Lichtsteiner SP, et al. The telomerase reverse transcriptase promoter drives efficacious tumour suicide gene therapy while preventing hepatotoxicity encountered with constitutive promoters. Gene Ther 2001; 8: 568-578.
25. 131I]MIBG and clonogenic cell kill. Oncogene 2001; 20: 7804-7808.
26. Nagasawa H, Little JB. Induction of sister chromatid exchanges by extremely low doses of alpha-particles. Cancer Res 1992; 52: 6394-6396.
27. Mothersill C, Seymour C. Radiation-induced bystander effects: past history and future directions. Radiat Res 2001; 155: 759-767.
28. Goldberg Z, Lehnert BE. Radiation-induced effects in unirradiated cells: a review and implications in cancer. Int J Oncol 2002; 21: 337-349.
29. Little JB. Genomic instability and bystander effects: a historical perspective. Oncogene 2003; 22: 6978-6987.
30. Boyd M, Livingstone A, Wilson LE, et al. The dose response relationship for radiation induced mutations at micro- and minisatellites loci in human somatic cells in culture. Int J Radiat Biol 2000; 76: 169-176.
31. Boyd M, Mairs SC, Stevenson K, et al. Transfectant mosaic spheroids: a new model for the evaluation of bystander effects in experimental gene therapy. J Gene Med 2002; 4: 1-10.
32. 131I]iodobenzylguanidine. Appl Radiat Isot 1993; 44: 621-628.
33. 131I]-metaiodobenzylguanidine: comparison of production from metaiodobenzylguanidine and from meta-trimethylsilylbenzylguanidine. Nucl Med Commun 1994; 15: 268-274.
34. 211AT]astatobenzylguanidine: synthesis via astato demetalation and preliminary in vitro and in vivo evaluation. Bioconjugate Chem 1992; 3: 499-503.
35. Wheldon TE, Brunton GF. Relation of growth delay to cure for experimental tumour systems conforming to Poisson cure statistics. Br J Cancer 1982; 45: 1-9.
36. 211At]astatobenzylguanidine on human neuroblastoma cells. Cancer Res 1994; 54: 5414-5419.
37. Counter CM, Hirte HW, Bacchetti S, et al. Telomerase activity in human ovarian cancer. Proc Natl Acad Sci U S A 1994; 91: 2900-2904.
38. Keith WN, Evans TRJ, Glasspool RM. Telomerase and cancer: time to move from a promising target to a clinical reality. J Pathol 2001; 195: 404-414.
39. Sisson JC, Hutchinson RJ, Shapiro B. Iodine-125-MIBG to treat neuroblastoma: preliminary report. J Nucl Med 1990; 31: 1479-1485.
40. 125I]metaiodobenzylguanidine. J Nucl Biol Med 1991; 35: 255-259.
41. Hoefnagel CA, Smets L, Voute PA, et al. Iodine-125-MIBG therapy for neuroblastomas. J Nucl Med 1991; 32: 361-362.
42. Sutherland RM. Cells and environment interactions in tumour microregions; the multicell spheroid model. Science 1998; 240 177-184.
43. Boyd M, Spenning HS, Mairs RJ. Radiation and gene therapy: rays of hope for the new millennium. Curr Gene Ther 2003; 3: 319-339.
44. Lehnert BE, Goodwin EH. Extracellular factor(s) following exposure to alpha particles can cause sister chromatid exchanges in normal human cells. Cancer Res 1997; 57: 2164-2171.
45. Narayanan PK, Goodwin EH, Lehnert BE. Alpha particles initiate the biological production of superoxide anions and hydrogen peroxide in human cells. Cancer Res 1997; 57: 3963-3971.
46. Narayanan PK, LaRue KEA, Goodwin EH, et al. Alpha particles induce the production of interleukin-8 by human cells. Radiat Res 1999; 152: 57-63.
47. Mothersill C, Seymour C. Low-dose radiation effects: experimental haematology and the changing paradigm. Exp Haematol 2003; 31: 437-445.
48. Prise KM, Folkard M, Michael BD. Bystander responses induced by low LET radiation. Oncogene 2003; 22: 7043-7049.
49. Knisely JPS, Rockwell S. Importance of hypoxia in the biology and treatment of brain tumors. Neuroimaging Clinics North America 2002; 12: 525-536.